Nicholson Nur — SEC insider filings

SEC reporting owner CIK 1827317. 23 insider filings on record with FilingPulse; latest filed 2026-09-09.

Transaction summary — filings shown

Covers all 23 filings on record, filed 2021-02-01 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Apellis Pharmaceuticals, Inc. (APLS)Chief Technical Officer22—14 legs · 58,951 sh · $2,446,91342
Kailera Therapeutics, Inc. (KLRA)Chief Technology Officer1——1

Insider filings — Nicholson Nur

FiledFormIssuerReported transactionsSource
2026-09-094Kailera Therapeutics, Inc. (KLRA)Grant/award (A): 220,000 (derivative) @ $0EDGAR
2026-05-144Apellis Pharmaceuticals, Inc. (APLS)Code (U): 116,338 · Grant/award (A): 22,610 · Disposition to issuer (D): 22,610 · Grant/award (A): 45,220 · Disposition to issuer (D): 45,220 · Grant/award (A): 24,284 · +13 moreEDGAR
2026-01-304Apellis Pharmaceuticals, Inc. (APLS)Grant/award (A): 45,220 @ $0EDGAR
2026-01-234Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 7,725 @ $21.77EDGAR
2026-01-214Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 2,203 @ $19.79EDGAR
2026-01-154Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 2,618 @ $22.19EDGAR
2025-06-114Apellis Pharmaceuticals, Inc. (APLS)Grant/award (A): 82,500 (derivative) @ $19.39EDGAR
2025-01-304Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 825 @ $29.52EDGAR
2025-01-234Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 3,948 @ $30.43EDGAR
2025-01-214Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 2,145 @ $29.96 · Grant/award (A): 36,426 @ $0EDGAR
2025-01-144Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 2,632 @ $28.70EDGAR
2024-03-144Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 7,768 @ $57.31 · Sale (S): 3,452 @ $58.13EDGAR
2024-01-314Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 835 @ $64.14EDGAR
2024-01-234Apellis Pharmaceuticals, Inc. (APLS)Sale (S): 2,593 @ $65.00EDGAR
2024-01-174Apellis Pharmaceuticals, Inc. (APLS)Grant/award (A): 19,508 @ $0 · Sale (S): 1,857 @ $66.81 · Grant/award (A): 28,367 (derivative) @ $66.30EDGAR
2023-09-194Apellis Pharmaceuticals, Inc. (APLS)Option exercise (M): 9,719 @ $29.76 · Sale (S): 9,719 @ $42.21 · Sale (S): 10,631 @ $46.15 · Option exercise (M): 9,719 (derivative) @ $0EDGAR
2023-02-224Apellis Pharmaceuticals, Inc. (APLS)Grant/award (A): 9,886 @ $0 · Tax withholding (F): 825 @ $58.50 · Grant/award (A): 14,023 (derivative) @ $0EDGAR
2023-01-304Apellis Pharmaceuticals, Inc. (APLS)Tax withholding (F): 551 @ $52.77EDGAR
2023-01-244Apellis Pharmaceuticals, Inc. (APLS)Tax withholding (F): 2,034 @ $52.05EDGAR
2023-01-174Apellis Pharmaceuticals, Inc. (APLS)Other (J): 1,875 @ $0 · Grant/award (A): 22,580 @ $0 · Other (J): 11,250 (derivative) @ $0 · Grant/award (A): 35,472 (derivative) @ $52.66EDGAR
2022-02-014Apellis Pharmaceuticals, Inc. (APLS)Tax withholding (F): 650 @ $38.59EDGAR
2022-01-254Apellis Pharmaceuticals, Inc. (APLS)Grant/award (A): 26,051 @ $0 · Grant/award (A): 36,951 (derivative) @ $0EDGAR
2021-02-014Apellis Pharmaceuticals, Inc. (APLS)Grant/award (A): 7,500 @ $0 · Grant/award (A): 1,875 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 11,250 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-01-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1827317 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs